Additional SAR data
a Average of at least two measurements in diI uptake assay, ± standard of mean when n > 2.
Synthesis and characterization data for 17-11 (ML278)
General Details. All reagents and solvents were purchased from commercial vendors and used as received. NMR spectra were recorded on a Bruker 300 MHz or Varian UNITY INOVA 500 MHz spectrometer as indicated. Proton and carbon chemical shifts are reported in parts per million (ppm; δ) relative to tetramethylsilane, CDCl 3 solvent, or d 6 -DMSO ( 1 H δ 0, 13 C δ 77.16, or 13 C δ 39.5, respectively). NMR data are reported as follows: chemical shifts, multiplicity (obs.
= obscured, app = apparent, br = broad, s = singlet, d = doublet, t = triplet, m = multiplet, comp = complex overlapping signals); coupling constant(s) in Hz; integration. Unless otherwise indicated, NMR data were collected at 25 °C. Flash chromatography was performed using 40-60 µm Silica Gel on a Teledyne Isco Combiflash R f system. Tandem liquid chromatography/mass spectrometry (LCMS) was performed on a Waters 2795 separations module and Waters 3100 mass detector. Analytical thin layer chromatography (TLC) was performed on EM Reagent 0.25 mm silica gel 60-F plates. Visualization was accomplished with UV light and aqueous potassium permanganate (KMnO 4 ) stain followed by heating. High-resolution mass spectra were obtained at the MIT Mass Spectrometry Facility with a Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform Ion Cyclotron Resonance mass spectrometer. Compound purity and identity were determined by UPLC-MS (Waters, Milford, MA). Purity was measured by UV absorbance at 210 nm. Identity was determined on a SQ mass spectrometer by positive electrospray ionization. Mobile Phase A consisted of either 0.1% ammonium hydroxide or 0.1% trifluoroacetic acid in water, while mobile Phase B consisted of the same additives in acetonitrile. The gradient ran from 5% to 95% mobile Phase B over 0.8 minutes at 0.45 ml/min. An Acquity BEH C18, 1.7 µm, 1.0 x 50 mm column was used with column temperature maintained at 65 °C. Compounds were dissolved in DMSO at a nominal concentration of 1 mg/ml, and 0.25 µl of this solution was injected.
concentrated under reduced pressure to give a brown solid (3.91 g ). The crude material was purified by column chromatography over silica gel (hexanes/ethyl acetate: 100/0 to 0/100) to give the title compound as a tan solid (3.41 g, 88 %) . 1 H NMR (300 MHz, CDCl 3 ): δ 7. 87 -7.81 (m, 3H), 7.75 -7.69 (m, 2H), 7.65 -7.57 (m, 1H), 7.54 -7.47 (m, 2H) , 4.63 (s, 2H), 4.01 (t, J = 8.6 Hz, 2H), 3.05 (t, J = 8.6 Hz, 2H); MS (ESI + ): 336 (M+H).
2-Chloro-1-(indolin-5-yl)ethanone (14):
A microwave tube was charged with a magnetic stirbar and 2-chloro-1-(1-(phenylsulfonyl)indolin-5-yl)ethanone (3.26 g, 9 .54 mmol). Concentrated sulfuric acid (9.0 ml) was added, and the resulting suspension was microwaved for 10 minutes at 100 °C. The reaction was carefully poured into ice water (500 ml). The dark mixture was stirred while warming to room temperature then treated with 10% (w/v) aqueous sodium hydroxide (approximately 200 ml) until the pH >10. This mixture was then extracted with dichloromethane (3 x 250 ml). The combined extracts were washed with brine (200 ml), then shaken over magnesium sulfate, filtered, and concentrated under reduced pressure to give a brown solid (1.52 g). This material was used immediately without further purification. tert-Butyl 5-(2-aminothiazol-4-yl)indoline-1-carboxylate (15): 2-Chloro-1-(indolin-5-yl)ethanone (1.52 g, 7.75 mmol) was placed in a microwave vial and dissolved in anhydrous ethanol (30.0 mL) to give an opaque, black solution. Thiourea (0.66 g, 8.67 mmol) was added and the resulting mixture was microwaved for 30 minutes at 120 °C. 4-(N,NDimethylamino)pyridine (95.0 mg, 0.78 mmol) and N,N-diisopropylethylamine (1.5 ml, 9.3 mmol) were added to the reaction mixture. Neat di-tert-butyl dicarbonate (2.0 mL, 8.52 mmol) was added last, and the reaction was stirred at room temperature for 1 hour. The opaque, redbrown mixture was concentrated under reduced pressure to give a red-brown solid. This material was partitioned between water (50 ml) and ethyl acetate (75 ml) and stirred at room temperature until everything dissolved. The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were shaken over magnesium sulfate, filtered, and concentrated under reduced pressure to give an orange-brown solid. The crude material was purified by column chromatography over silica gel (hexanes/ethyl acetate: 100/0 to 40/60) to give the title compound as an orange solid (1.72 g, 56 % over three steps tert-Butyl 5-(2-(3,5-dimethoxybenzamido)thiazol-4-yl)indoline-1-carboxylate (16): In a round-bottom flask equipped with a magnetic stirbar, tert-butyl 5-(2-aminothiazol-4-yl)indoline-1-carboxylate (0.500 g, 1.58 mmol) was combined with 4-(N,N-dimethylamino)pyridine (19.0 mg, 0.16 mmol). Dichloromethane (4.0 ml) was added to produce an orange suspension that was cooled to 0 °C. N,N-Diisopropylethylamine (0.33 ml, 1.89 mmol) was added followed by a solution of 3,5-dimethoxybenzoyl chloride (0.35 g, 1.73 mmol) in dichloromethane (1.00 ml). The bright orange mixture was stirred for 1 hour while warming to room temperature. The resulting clear, red-brown solution was diluted with saturated sodium bicarbonate solution (aqueous, 10 ml) and dichloromethane (10 ml). The layers were separated, and the aqueous phase was extracted with dichloromethane (3 x 10 ml). The combined organics were washed with brine (10 ml) then shaken over magnesium sulfate, filtered, and concentrated under reduced pressure to give a thick, orange-brown oil. This material was purified by column chromatography over silica gel (hexanes/ethyl acetate: 100/0 to 70/30) to give the title compounds as a light yellow solid (0.51 g, 67% 
(M+H).
N-(4-(Indolin-5-yl)thiazol-2-yl)-3,5-dimethoxybenzamide, trifluoroacetic acid salt: tertButyl 5-(2-(3,5-dimethoxybenzamido)thiazol-4-yl)indoline-1-carboxylate (0.38 g, 0.79 mmol) was placed in a round-bottom flask with a magnetic stirbar and dissolved in dichloromethane (5.3 mL) to give a clear, yellow solution. Triethylsilane (1.3 mL, 7.93 mmol) was added followed by 2,2,2-trifluoroacetic acid (1.2 mL, 15.9 mmol), and the reaction quickly turned light orange and produced a gas. The reaction was stirred at room temperature for 1 hour. The light pink reaction was concentrated under reduced pressure to give a rose-colored solid. The crude material was suspended in diethyl ether (10 ml) and filtered. The collected solids were washed 3,5-Dimethoxy-N-(4-(1-(2-methoxyacetyl)indolin-5-yl)thiazol-2-yl)benzamide (17-11, ML278): A round-bottom flask equipped with a magnetic stir bar was charged with 5-(2-(3,5-dimethoxybenzamido)thiazol-4-yl)indolinium 2,2,2-trifluoroacetate (75.0 mg, 0.15 mmol). Dichloromethane (1.5 ml) was added to produce a purple suspension that was cooled to 0 °C. 4-(N,N-Dimethylamino)pyridine (1.8 mg, 0.015 mmol) was added, followed by N,Ndiisopropylethylamine (79 µl, 0.45 mmol) to give a clear, dark solution. 2-Methoxyacetyl chloride (15 µl, 0.17 mmol) was added last. The reaction was warmed to room temperature and stirred for 1 hour. The cloudy, tan mixture was diluted with dichloromethane (2 ml) and quenched with saturated sodium bicarbonate (aqueous, 2 ml). The layers were separated, and the aqueous portion was extracted with additional hot ethyl acetate (5 x 3 ml), with both layers heated to ~50 °C. The combined organic layers were shaken over magnesium sulfate, filtered, and concentrated under reduced pressure to give a light tan solid. The crude material was purified by column chromatography over silica gel (dichloromethane/methanol: 100/0 to 97/3) to give the title compound as an off-white solid (54.3 mg, 79 % 158.2, 150.0, 142.7, 133.9, 131.4, 130.3, 125.7, 122.2, 117.1, 107.3, 105.2, 105.0, 72.3, 59.4, 55.6, 46.8, 28 (Table S2 ) and curves were plotted using non-linear regression analysis (4 parameters), using GraphPad Prism v. 6. a Average of at least two measurements in DiI uptake assay, ± standard error of mean when n > 2. NT = not tested.
Probe comparison

Compound profiling protocols
Solubility. Solubility was determined in phosphate buffered saline (PBS) pH 7.4 with 1% DMSO. Each compound was prepared in duplicate at 100 µM in both 100% DMSO and PBS with 1% DMSO. Compounds were allowed to equilibrate at room temperature with a 250 rpm orbital shake for 24 hours. After equilibration, samples were analyzed by UPLC-MS (Waters, Milford, MA) with compounds detected by SIR detection on a single quadrupole mass spectrometer. The DMSO samples were used to create a two-point calibration curve to which the response in PBS was fit. 
Assay protocols
Materials and Reagents
• DiI-HDL, custom purified HDL particles derived from human blood were prepared and labeled with 1,1 '-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
Cell Lines
The following cell lines were used in this study:
• ldlA[mSR-BI] is a Chinese hamster ovary (CHO) cell line that overexpresses murine SR-BI, isoform 1 (NP_058021) and lacks the LDL receptor was obtained from the Assay Provider (Krieger Laboratory). This cell line was used for the primary assay and several secondary assays. A variant of this cell line expressing mutant SR-BI, where a cysteine required for interaction with BLT-1 is mutated to serine (C384S SR-BI), was used in several secondary assays. The ldlA[mSR-BI] cells used in the assay were a CHO cell line lacking expression of the LDL receptors and overexpressing the Scavenger receptor (SR-BI). Inhibitors of SR-BI and HDL-mediated uptake lead to a reduction in fluorescence in this assay. Fluorescence was measured using a PerkinElmer EnVision plate reader. Primary HTS data were analyzed in Genedata Screener Assay Analyzer, and were normalized against DMSO and 1 µM BLT-1 (positive control). For the HTS, the average of two replicates was used to rank order activity and to choose compounds for retests. For dose studies, the curves were generated with Genedata Condeseo and showed percent (%) activity for the individual doses. + 10 ug protein/ml DiI-HDL with Thermo Combi fluid handler (slow speed setting). 3. Pin transfer 100 nL compounds and positive control (1 uM BLT-1). It is recommended that low solubility compounds (such as ML278) be sonicated in DMSO to ensure complete dissolution prior to preparing stock solutions. 4. Incubate 3 hours @ 37°C in humidified cell culture incubator. 5. Remove media with aspirator. 6. Wash twice with 30 uL PBS (+Ca and Mg) using the Thermo Combi on slow speed setting. 7. Analyze DiI-HDL uptake with Perkin-Elmer EnVision plate reader (Bodipy TMR mirror #405, excitation filter is Photometric 550 (#312) and emission filter is Cy3 595 (#229) with bottom read.
b) HDL Binding Assay
HDL binding was assessed using Alexa Fluor 488-labeled HDL particles. For this assay, the Alexa 488 dye was covalently bound to apolipoprotein components of the HDL particle via primary amines; thus, no transfer of the fluorophore to cell membranes occurs. In this manner, direct binding of the HDL particles to SR-BI can be measured. As a positive control, BLT-1 was used at 1 µM, which is known to increase binding of HDL to SR-BI. It is possible that a compound can reduce binding of HDL to the receptor, and this would lead to a decrease in signal. This assay is used to characterize the mechanism of action of a particular compound; therefore, any outcome in the assay is acceptable. Data were normalized against DMSO and BLT-1 (positive control) wells in Genedata Assay Analyzer. Curves were generated with Genedata Condeseo and showed percent (%) activity for the individual doses. of 10 ug/mL and incubate 2 hours at 37°C in a humidified cell culture incubator 5. Remove the medium at the end of incubation at 4C 6. Wash the plates 2X with Tris-BSA buffer and 1X Tris-HCl buffer. 7. Add 1 ml isopropanol, and incubate for 20 min at 4C. 8. Collect 1 ml isopropanol/lysate into counting tube, add 4 ml liquid scintillation buffer, and prepare for counting. 9. Specific uptake is the difference between total and nonspecific activities. 10. Data were analyzed using Prism 6 (GraphPad Software).
11. All calculated errors represent standard errors of the mean. 
e) HDL isolation and labeling
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Study Objectives
To evaluate, in LeadProfilingScreen, the activity of test compound BRD-K83634925-001-01-1 (Ricerca # 1162315).
Services Performed
LeadProfilingScreen (Total # of Assays: 67)
Study Signatures
"This study was conducted according to the procedures described in this report. All data presented are authentic, accurate and correct to the best of our knowledge. 
Summary
STUDY OBJECTIVE
To evaluate, in Radioligand Binding assays, the activity of compound BRD-K83634925-001-01-1 (BRD-9, PT# 1162315).
METHODS
Methods employed in this study have been adapted from the scientific literature to maximize reliability and reproducibility. Reference standards were run as an integral part of each assay to ensure the validity of the results obtained. Assays were performed under conditions described in the accompanying "Methods" section of this report.
Where presented, IC50 values were determined by a non-linear, least squares regression analysis using MathIQ TM (ID Business Solutions Ltd., UK 
Summary of Significant Results
Biochemical assay results are presented as the percent inhibition of specific binding or activity throughout the report. All other results are expressed in terms of that assay's quantitation method.
• For primary assays, only the lowest concentration with a significant response judged by the assays' criteria, is shown in this summary.
• Where applicable, either the secondary assay results with the lowest dose/concentration meeting the significance criteria or, if inactive, the highest dose/concentration that did not meet the significance criteria is shown.
• Unless otherwise requested, primary screening in duplicate with quantitative data (e.g., IC50 ± SEM, Ki ± SEM and nH)
are shown where applicable for individual requested assays. In screening packages, primary screening in duplicate with semi-quantitative data (e.g., estimated IC50, Ki and nH) are shown where applicable (concentration range of 4 log units); available secondary functional assays are carried out (30 mM) and MEC or MIC determined only if active in primary assays >50% at 1 log unit below initial test concentration.
Significant responses (≥ 50% inhibition or stimulation for Biochemical assays) were noted in the primary assays listed below:
No significant results noted. 
